SINTX TECHNOLOGIES, INC.
SINT Healthcare Medical Devices
SINTX TECHNOLOGIES, INC.’s revenue for fiscal 2025 (year ended December 2025) was $1.0 million, down 64.7% from fiscal 2024. In the quarter to June 2026, revenue grew 199.3%, EPS grew 17.6%, free cash flow fell 38.6% and total debt fell 6.42%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
Follow SINT
SINTX TECHNOLOGIES, INC. (SINT) EV/Sales
As of 16 October 2026, SINTX TECHNOLOGIES, INC. (SINT) trades at a EV/Sales of 3.7×. Over the past ten years it has ranged from −7.6× (April 2020) to 14,646,393× (July 2015); the current reading is higher than 49% of that period. That is above the Medical Devices industry median of 2.2× and above the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 6.5× | — |
| FY2024 | −0.3× | — |
| FY2023 | −0.7× | — |
| FY2022 | −1.8× | — |
| FY2021 | 5.8× | 2,004.00% |
| FY2020 | 0.3× | (84.19%) |
| FY2019 | 1.8× | — |
| FY2018 | −0.4× | — |
| FY2016 | 472,387× | 97.52% |
| FY2015 | 239,163× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 4.2× | (47.65%) |
| Mar 2026 | 8.0× | 24.16% |
| Dec 2025 | 6.5× | 38.25% |
| Sep 2025 | 4.7× | 119.62% |
| 36 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| RBOT Vicarious Surgical Inc. compare | n/m |
| IRIX IRIDEX Corporation compare | 0.3× |
| CTSO Cytosorbents Corporation compare | 0.7× |
| LFWD Lifeward Ltd. compare | 0.9× |
| BTCY Biotricity Inc. compare | 1.7× |
| SINT SINTX TECHNOLOGIES, INC. | 3.7× |
| ALUR Allurion Technologies, Inc. compare | 5.3× |
| PETV PetVivo Holdings, Inc. compare | 23.4× |
| HSCS HeartSciences Inc. compare | 556× |
| Medical Devices industry median | 2.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)